Clinical Trials

Drug company initiates clinical testing of West Nile virus assay in Canada

Published in Medical Letter on the CDC and FDA, September 26th, 2004

Spectral Diagnostics Inc. (SDI) and its joint venture research and development company, IDx Inc., has initiated clinical testing for its rapid assay used for detecting human infection with the West Nile Virus. This testing is being conducted at a public health laboratory in Canada.

Spectral received a license from the U.S. Centers for Disease Control for use of their reagents to develop a rapid assay for exposure to the West Nile Virus. Spectral's assay detects a patient's response to the West Nile Virus and is most useful for the many patients who present with nonspecific flu-like symptoms following recent exposure to potentially infected mosquitoes.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry